Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery


Although the number of annual drug approvals has recently been trending upward[1], the number of first in class therapies has remained relatively constant, often less than 10 per year. For such new medicines for pioneer targets, the level of attrition in Phase II proof-of-concept clinical studies remains the biggest hurdle[2], in large part because the target-disease associations derived from the currently dominant cell or animal pre-clinical models of disease most often do not translate into clinical efficacy.

Thus, it is increasingly appreciated that the use of disease models based on human samples will be critical both to increase our understanding of pathophysiology and to improve the productivity of the sector. However, securing regular access to well-annotated samples from patients is challenging to organize, raises ethical issues and requires new organizational models.

To address this challenge, we have established a partnership between; i) the clinical academic community which cares for the patients and provides deep disease expertise; ii) the academic research community that provides the molecular and technological insights necessary for mechanistic studies; iii) the industrial pharmaceutical sector with its strength in e.g. the development of high quality chemical and antibody modulators of protein function and iv) with the engagement from Disease Foundations[3].


Within ULTRA-DD and the SGC Open-Source Target Discovery Partnership; our aim is to identify and validate under-explored protein targets by profiling the highest quality target-directed chemical and antibody probes in the highest quality patient-cell derived assays, providing biomarker and phenotypic read-outs in a more disease relevant context.

ULTRA-DD is focused on defining and validating novel targets in auto-immune and inflammatory diseases by the use of patient-cell derived assays. This is made possible by our collaborating clinicians and hospitals in Oxford and Stockholm, allowing us excellent access to tissue and cells from e.g. lupus, myositis, ankylosing spondylitis and dupuytren’s disease patients. Common co-morbidities for these patients indicate that the disease mechanisms could also be important in other indications, including IBD and RA, which will be explored through collaboration.